BioAlliance Pharma Announces: New Achievements in Clonidine Lauriad™ Clinical Development, Second Product of Its Orphan Oncology Portfolio

Published: Apr 17, 2012

PARIS--(BUSINESS WIRE)--Regulatory News: “Beyond optimizing the product development, the expansion of our trial in Europe enables us to already involve a great number of specialists, part of our future prescriber network” BioAlliance Pharma SA (Paris:BIO), a Company dedicated to specialty and orphan pharma products in oncology and supportive care, today announces new achievements in its phase II clinical trial with clonidine Lauriad™.

Back to news